Office of Technology Transfer and Development

Cultiviating Tomorrow's Technology Today

From the Director, NHLBI
Elizabeth G. Nabel, M.D.

The National Heart, Lung, and Blood Institute (NHLBI) views technology transfer as a unique opportunity to expedite the transfer of research results to improve public health while simultaneously establishing collaborative relationships with industry. Federal legislation, including the Federal Technology Transfer Act of 1986 and the subsequent National Technology Transfer Advancement Act of 1996, empowers the Institute to interact directly with industry to translate our research results into commercial products that benefit public health.

The NHLBI has seized this opportunity, offering its leading edge technology to industry for further development and commercialization. The research of the Institute's 300 tenured doctoral level scientists and post doctoral fellows has resulted in the development of many innovative heart, lung and blood-related technologies. Scientific areas of expertise include: molecular immunology, genetic therapy, biochemical genetics, cell biology and metabolism, magnetic resonance imaging, and clinical research (e.g., hypertrophic cardiomyopathy, bone marrow transplantation). By matching our promising technologies with appropriate industrial partners, we are now able to transfer research results more efficiently from the bench to the bedside for the benefit of the nation's health. The NHLBI Office of Technology Transfer and Development (OTTAD) is responsible for the implementation of Cooperative Research and Development Agreements (CRADAs), Clinical Trial Agreements, Material Transfer Agreements (MTAs), and licensing arrangements. For more information on establishing collaborative research agreements or pursuing licensing opportunities, please contact OTTAD.